{"id":"NCT02151253","sponsor":"Duke University","briefTitle":"Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia","officialTitle":"A Double-Blind, Placebo-Controlled, Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2011-05","primaryCompletion":"2015-09","completion":"2015-09","firstPosted":"2014-05-30","resultsPosted":"2017-03-24","lastUpdate":"2017-03-24"},"enrollment":81,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Nocturia","Daytime Sleepiness"],"interventions":[{"type":"DRUG","name":"Armodafinil","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Armodafinil First, Then Placebo","type":"EXPERIMENTAL"},{"label":"Placebo First, Then Armodafinil","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of the study is to evaluate armodafinil as a wakefulness-promoting therapy as a means of improving residual daytime sleepiness in patients with treated nocturia.","primaryOutcome":{"measure":"Change From Baseline in Epworth Sleepiness Scale [ESS]","timeFrame":"Baseline, Week 4 of each phase","effectByArm":[{"arm":"Armodafinil","deltaMin":9.03,"sd":5.18},{"arm":"Placebo","deltaMin":9.73,"sd":4.43}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":28},"commonTop":["Upper Respiratory Infection","Anxiety/Jitteriness","Nausea","Sinus Infection","insomnia"]}}